Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis

AIM: Fuzhenghuayu (FZHY) capsule can inhibit the progression of cirrhosis. This study explored whether FZHY can reduce the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B-caused cirrhosis (HBC) undergoing antiviral therapy. METHODS: A retrospective review of 842 patients wit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Evid Based Complement Alternat Med
Egile Nagusiak: Shi, Ke, Liu, Yao, Wang, Xiaojing, Li, Yuxin, Zhang, Qun, Hu, Ying, Ran, Chongping, Huang, Yunyi, Hou, Jie, Wang, Xianbo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2020
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7644307/
https://ncbi.nlm.nih.gov/pubmed/33178324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8826091
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak